Ceftobiprole

Ceftobiprole
  • CAS No.:209467-52-7
Other grades of this product :

Ceftobiprole Basic information
Product Name:Ceftobiprole
Synonyms:Ceftobiprole;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid,7-[[(2Z)-2-(5-aMino-1,2,4-thiadiazol-3-yl)-2-(hydroxyiMino)acetyl]aMino]-8-oxo-3-[(E)-[(3'R)-2-oxo[1,3'-bipyrrolidin]-3-ylidene]Methyl]-,(6R,7R)-;CS-734;BAL 9141;209467-52-7
CAS:209467-52-7
MF:C20H22N8O6S2
MW:534.57
EINECS:
Product Categories:
Mol File:209467-52-7.mol
Ceftobiprole Chemical Properties
density 2.00±0.1 g/cm3(Predicted)
pka2.46±0.50(Predicted)
Safety Information
MSDS Information
Ceftobiprole Usage And Synthesis
UsesBroad spectrum antibiotic.
Antimicrobial activityThe most important property distinguishing it from older cephalosporins is activity against methicillin-resistant staphylococci, a property conferred by a high affinity for penicillinbinding protein 2′ (2a). MICs for methicillin-resistant strains are nevertheless somewhat higher than those seen with fully susceptible strains. A similar situation exists with coagulasenegative staphylococci and with Str. pneumoniae, for which strains with reduced susceptibility to penicillin are less susceptible than fully resistant strains, while remaining within therapeutically achievable levels. Otherwise activity approximates to that of cephalosporins of group 4 . Activity against Ps. aeruginosa is modest and much reduced against ceftazidime-resistant strains.
Acquired resistanceIt is hydrolyzed by extended spectrum β-lactamases of enterobacteria , which are therefore resistant. The prospects for the emergence of resistance during extensive clinical use are presently unclear, though increased resistance in Staph. aureus appears to be difficult to induce under laboratory conditions.
PharmacokineticsCmax 500 mg (667 mg prodrug): c. 35 mg/L end infusion intravenous (30-min infusion) Plasma half-life: c. 3 h Volume of distribution: 18.4 L Plasma protein binding: 16% The prodrug is rapidly hydrolyzed in plasma to release the active form together with diacetyl (2,3-butanediol) and CO2. Distribution approximates to the extracellular fluid volume in adults. There is no accumulation on repeat dosing in subjects with normal renal function. It is chiefly excreted in urine by glomerular filtration. A urinary concentration exceeding 1 g/L is achieved within the first 2 h of a 500 mg (active drug equivalent) dose and 80–90% of active drug can be recovered within 24 h.
Clinical UseCeftobiprole can be used as Broad spectrum antibiotic and in complicated infections of skin and skin structures.
Side effectsLimited studies have so far revealed no unexpected side effects. Nausea, vomiting and altered taste sensation appear to be the most common.
Ceftobiprole Preparation Products And Raw materials

Welcome!

Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.

  • NO. 18 ,Wujiang Road, Wulidian Street, Jiangbei District, Chongqing
  • +86-23-6139-8061 +86-13650506873
  • danny@chemdad.com sales@chemdad.com
  • www.chemdad.com
  • WhatsApp +86-13650506873

Name

phone

company

email

message

Payment methods
Google translate: 日本语日本语 한국어한국어 FrançaisFrançais DeutschDeutsch EspañaEspaña TürkiyeTürkiye